Table 1.
Clinical characteristics of colorectal cancer patients.
| Clinical features | Number (%)a |
|---|---|
| Gender - no. (%) | |
| Female | 248 (45.01) |
| Male | 303 (54.99) |
| Age - years | |
| Median | 68 |
| Range | 24-91 |
| Location - no. (%)b | |
| Ascending colon | 151 (27.40) |
| Transverse colon | 24 (4.36) |
| Descending colon | 48 (8.71) |
| Sigmoid colon | 141 (25.59) |
| Rectum | 182 (33.03) |
| Missing data | 10 (1.81) |
| TNM stage - no. (%)c | |
| I | 53 (9.62) |
| II | 267 (48.46) |
| III | 192 (34.85) |
| IV | 22 (3.99) |
| Missing | 17 (3.09) |
| Pathological type - no. (%) | |
| Tubular adenocarcinoma | 442 (80.22) |
| Mucinous adenocarcinoma | 57 (10.34) |
| Mixed adenocarcinoma | 52 (9.44) |
| Tumor size - no. (%) | |
| < 5 cm | 245 (44.46) |
| ≥ 5 cm | 250 (45.37) |
| Missing data | 56 (10.16) |
| Lymph node metastasis - no. (%) | |
| Yes | 201 (36.48) |
| No | 337 (61.16) |
| Missing data | 13 (2.36) |
| Differentiation -no. (%) | |
| Well | 59 (10.71) |
| Moderate | 356 (64.61) |
| Poor | 136 (24.68) |
| Postoperative adjuvant chemotherapy - no. (%)d | |
| Yes | 247 (44.83) |
| No | 281 (51.00) |
| Missing data | 23 (4.17) |
| Intraoperative chemotherapy - no. (%)e | |
| Yes | 193 (35.03) |
| No | 331 (60.07) |
| Missing data | 27 (4.90) |
| Survival - no. (%) | |
| Median | 63.97 |
| Range | 0.13 - 117.93 |
aPercentages may not sum to 100 because of rounding. bTumor location was available for 542 patients in the current study. Four patients had both rectal and sigmoid colon cancer, and 1 patient had both descending colon and sigmoid colon cancer. cTNM denotes tumor-node-metastasis. dDetailed information pertaining to the receipt of postoperative adjuvant chemotherapy was available for 247 patients in the current study. Chemotherapy was primarily fluorouracil based with or without leucovorin, levamisole, or cisplatin. eDetailed information pertaining to the receipt of intraoperative chemotherapy was available for 193 patients in the current study. The intraoperative chemotherapy regimens consisting of hydroxycamptothecin, calcium folinate (TNF), 5-fluorouracil (5-FU), and calcium folinate (CF) were administered during the operations. Hydroxycamptothecin was used as peritoneal irrigation during the operations, whereas TNF, 5-FU, and CF were given as intravenous injections. fStandard of the 7th TNM stage of International Union Against Cancer (UICC) was used in our study